Atibuclimab

Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS) -induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury[1][2].

Product Specifications

CAS Number

[2417175-94-9]

Product Name Alternative

IC14

UNSPSC

12352203

Target

Toll-like Receptor (TLR)

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/atibuclimab.html

Purity

99.06

Solubility

H2O

Smiles

[Atibuclimab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]Henderson RD, Agosti JM, McCombe PA, et al. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (Baltimore) . 2021;100 (42) :e27421. |[2]Verbon A, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol. 2001;166 (5) :3599-3605.